Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma
| Autor: | Peter I. Croucher, Andrew D Chantry, Deborah J. Heath, Evgenia Verrou, Evangelos Terpos, Athanasios Anagnostopoulos, Meletios-Athanassios Dimopoulos, Kostas Zervas, Eirini Katodritou, Amin Rahemtulla, Anastasia Pouli, Elisavet-Christine Vervessou |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male medicine.medical_specialty Bone disease Acid Phosphatase Osteocalcin Zoledronic Acid Collagen Type I Statistics Nonparametric Bone remodeling Bortezomib Osteoprotegerin Recurrence Internal medicine medicine Humans Protease Inhibitors Multiple myeloma Aged Aged 80 and over biology Diphosphonates Tartrate-Resistant Acid Phosphatase RANK Ligand Acid phosphatase Imidazoles Hematology Middle Aged medicine.disease Alkaline Phosphatase Boronic Acids Isoenzymes Endocrinology RANKL Case-Control Studies Pyrazines Cancer research biology.protein Intercellular Signaling Peptides and Proteins Female Bone Remodeling Multiple Myeloma Peptides Biomarkers medicine.drug |
| Zdroj: | British journal of haematology. 135(5) |
| ISSN: | 0007-1048 |
| Popis: | Summary The effect of bortezomib on bone remodelling was evaluated in 34 relapsed myeloma patients. At baseline, patients had increased serum concentrations of dickkopf-1 (DKK-1), soluble receptor activator of nuclear factor-jB ligand (sRANKL), sRANKL/osteoprotegerin ratio, C-telopeptide of type-I collagen (CTX) and tartrate-resistant acid phosphatase isoform-5b (TRACP-5b); bone-alkaline phosphatase and osteocalcin were reduced. Serum DKK-1 correlated with CTX and severe bone disease. Bortezomib administration significantly reduced serum DKK-1, sRANKL, CTX, and TRACP-5b after four cycles, and dramatically increased bone-alkaline phosphatase and osteocalcin, irrespective of treatment response. This is the first study showing that bortezomib reduces DKK-1 and RANKL serum levels, leading to the normalisation of bone remodelling in relapsed myeloma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text